Skip to Main content Skip to Navigation
Journal articles

A novel synthetic inhibitor of CDC25 phosphatases: BN82002.

Abstract : CDC25 dual-specificity phosphatases are essential regulators that dephosphorylate and activate cyclin-dependent kinase/cyclin complexes at key transitions of the cell cycle. CDC25 activity is currently considered to be an interesting target for the development of new antiproliferative agents. Here we report the identification of a new CDC25 inhibitor and the characterization of its effects at the molecular and cellular levels, and in animal models. BN82002 inhibits the phosphatase activity of recombinant human CDC25A, B, and C in vitro. It impairs the proliferation of tumoral cell lines and increases cyclin-dependent kinase 1 inhibitory tyrosine phosphorylation. In synchronized HeLa cells, BN82002 delays cell cycle progression at G1-S, in S phase and at the G2-M transition. In contrast, BN82002 arrests U2OS cell cycle mostly in the G1 phase. Selectivity of this inhibitor is demonstrated: (a) by the reversion of the mitotic-inducing effect observed in HeLa cells upon CDC25B overexpression; and (b) by the partial reversion of cell cycle arrest in U2OS expressing CDC25. We also show that BN82002 reduces growth rate of human tumor xenografts in athymic nude mice. BN82002 is a original CDC25 inhibitor that is active both in cell and animal models. This greatly reinforces the interest in CDC25 as an anticancer target.
Document type :
Journal articles
Complete list of metadata
Contributor : Bernard Ducommun <>
Submitted on : Wednesday, September 3, 2008 - 3:05:02 PM
Last modification on : Wednesday, January 20, 2021 - 3:22:04 PM


  • HAL Id : hal-00317444, version 1
  • PUBMED : 15126376



Marie-Christine Brezak, Muriel Quaranta, Odile Mondésert, Marie-Odile Galcera, Olivier Lavergne, et al.. A novel synthetic inhibitor of CDC25 phosphatases: BN82002.. Cancer Research, American Association for Cancer Research, 2004, 64 (9), pp.3320-5. ⟨hal-00317444⟩



Record views